RedHill Biopharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDHL research report →
Price Chart
About the company
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea.
- CEO
- Dror Ben-Asher
- IPO
- 2013
- Employees
- 13
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on RDHL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $883.14K
- P/E
- -0.28
- PEG
- -0.00
- P/S
- 0.43
- P/B
- -0.47
- EV/EBITDA
- 0.53
- Div Yield
- 0.00%
- Gross Margin
- 60.60%
- Op Margin
- -309.88%
- Net Margin
- -400.52%
- ROE
- -438.17%
- ROIC
- -680.30%
Latest fiscal year · YoY change
- Revenue
- $286.00K-96.4%
- Gross Profit
- $286.00K-94.1%
- Op Income
- $-7,909,000
- Net Income
- $-429,000+94.8%
- EPS
- $0.00+100.0%
- OCF Growth
- -3.0%
- FCF Growth
- -3.0%
- 52W High
- $1.60
- 52W Low
- $0.28
- 50D MA
- $0.47
- 200D MA
- $0.75
- Beta
- 4.87
- RSI (14)
- 25
- Avg Volume
- 2.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
RedHill said Q1 reflected record prescription momentum for Movantik and Talicia, while aggressive cost cuts are aimed at reaching cash flow from operations in the second half of 2022.· June 23, 2022
- Record quarterly prescription volume, with Movantik near record levels and Talicia at its best-ever quarterly prescription performance.
- Management said it is targeting positive cash from operations in the second half of 2022 and expects about $50 million of savings over 18 months.
- Cash used in operating activities fell more than 70% in Q1 to about $4 million, helped by lower R&D and a reduced commercial footprint.
- Talicia gained additional payer coverage, including Medi-Cal, Florida Medicaid and a national PBM win effective July 1.
- R&D remains focused on opaganib, RHB-107 and RHB-204, with external funding and partnerships expected to support much of development.
RedHill reported Q1 net revenues of $18.2 million, compared with $22.1 million in Q4 2021. Gross profit was $10.2 million, equal to a 56% gross margin, and cash used in operating activities fell to approximately $4 million from approximately $15 million in Q4 2021, a reduction of more than 70%. R&D expense was $3.1 million versus $5.9 million in Q4 2021, and cash at March 31 was approximately $45 million before a later $15 million registered direct offering in May. For guidance, management is targeting positive cash flow from operations before interest payments starting in the second half of 2022 and expects approximately $50 million in operational cost savings over the next 18 months, with the savings pace described as roughly spread across the next six quarters.
Dror Ben-Asher framed the quarter as a deliberate pivot toward financial independence, emphasizing cash preservation, earlier breakeven and disciplined cost control. He said the company is “decisive about controlling its own destiny,” pointed to the workforce reduction and SG&A/R&D streamlining, and reiterated that RedHill still sees growth from its commercial portfolio and possible acquisitions of revenue-generating products. His tone was guarded but confident, stressing that the changes were difficult but necessary and that the company is better positioned for growth and cash generation.
Micha Ben-Chorin focused on the financial reset: Q1 revenues were $18.2 million, gross profit $10.2 million with a 56% margin, and cash used in operating activities improved to about $4 million from about $15 million in Q4. He said R&D expense fell to $3.1 million from $5.9 million, cash was approximately $45 million at quarter-end before the May financing, and the cost reduction plan should deliver about $50 million in savings over the next 18 months. He also clarified that the company is including SG&A and selling expenses in its cash-flow-from-operations target, excluding stock compensation because it is a cash measure.
Analysts pressed on the 1/3 reduction in the U.S. commercial team, gross-to-net trends, cash runway, and whether RedHill could truly reach cash-flow-positive operations given the current cost structure. Management said territories were analyzed and consolidated, some white space will be covered by customer engagement specialists, and the reorganization was done to support revenue targets into 2023. On cash flow, management said the goal includes all selling, general and administrative expenses, that stock comp is excluded because it is non-cash, and that R&D should continue falling as COVID programs rely more on external funding. On RHB-204, management said outside capital or partners could speed enrollment and that, with support, they hope to enroll within 1.5 years.
The strongest bull case from the call is that both lead commercial brands are still growing: Movantik held nearly 74% PAMORA share and Talicia posted 12.8% quarter-over-quarter prescription growth and 80% year-over-year growth. Management also highlighted expanding payer access for Talicia and said new weekly prescription records in June suggest momentum carried into Q2. On the financial side, the company said it already cut operating cash burn sharply and is aiming for positive operating cash flow in the second half of 2022.
The main bear case is that revenue still declined sequentially, with Q1 net revenue down to $18.2 million from $22.1 million in Q4, while the company is still not profitable and is relying on major cost cuts to bridge the gap. Management also said future R&D funding will depend heavily on grants, partnerships and other external sources, which introduces execution risk. On the clinical side, several programs remain dependent on confirmatory studies, regulatory pathways and possible partner support, especially for opaganib, upamostat and RHB-204.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.6%
- Shares Outstanding
- 3.14M
- Float Shares
- 2.28M
of shares held by institutions
43 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eaton Vance Management | 40.42K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Raday Gilead | sell | 14,310,000 |
| Oct 1, 26 | Raday Gilead | other | 27,560,000 |
| Jul 10, 26 | Raday Gilead | sell | 14,130,000 |
| Jul 10, 26 | Raday Gilead | other | 28,150,000 |
| Apr 6, 26 | Raday Gilead | sell | 15,740,000 |
| Apr 6, 26 | Raday Gilead | other | 30,780,000 |
| Mar 18, 26 | Tsimchi Ofer | other | 0 |
| Mar 18, 26 | Tsimchi Ofer | other | 0 |
| Mar 18, 26 | Tsimchi Ofer | other | 0 |
| Mar 18, 26 | Tsimchi Ofer | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RDHL coverage
Recent articles, reports, and earnings notes.
No research on RDHL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RDHL report →RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
prnewswire.com · Nov 17
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
prnewswire.com · Nov 2
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
prnewswire.com · Oct 19
Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)
defenseworld.net · Oct 6
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
prnewswire.com · Sep 30
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
defenseworld.net · Sep 21
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
prnewswire.com · Sep 1
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
prnewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.